Actively Recruiting
CD70-targeted immunoPET Imaging of Malignant Cancers
Led by RenJi Hospital · Updated on 2026-05-12
300
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.
CONDITIONS
Official Title
CD70-targeted immunoPET Imaging of Malignant Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18-80 years and of either sex
- Histologically confirmed or suspected diagnosis of renal cancer (especially clear cell renal cell carcinoma), lymphoma, or nasopharyngeal carcinoma
- Able to sign informed consent and comply with study requirements
You will not qualify if you...
- Pregnancy
- Severe liver or kidney failure
- Allergy to single-domain antibody radiopharmaceuticals
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, China, 200127
Actively Recruiting
Research Team
W
Weijun Wei, Ph.D. & M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here